ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Yoshiko Yasuda, Yasuhiro Maeda, Satoshi Hara, Motoyoshi Tanaka, Eiji Koike, Yoh Watanabe, Seiji Masuda, Harufumi Yamasaki, Katsumi Okumoto, Hiroyoshi Konishi, Yoshitaka Horiuchi, Hiroshi Hoshiai
We examined the effect of blocking the erythropoietin (Epo) signaling using an anti-Epo antibody, soluble form of Epo receptor (sEpoR) capable of binding to Epo or EpoR antagonist, and proved to be effective against xenografts of female reproductive organ mal…
Parvin Adimi, Karina Dahl Steffensen, Doris Schledermann, Eva Rye Rasmussen, Anders Jakobsen
Objectives. Locally advanced cervix cancer represents a therapeutic challenge with a delicate balance between effect and toxicity. Consequently, there is an obvious need for new prognostic parameters with a perspective of a more individualized treatment. The…
Michelle Kelleher, William Shingler, Robert E. Hawkins, Alan Anthoney, Richard Harrop
Modified vaccinia Ankara (MVA) virus encoding the tumor antigen 5T4 (MVA-5T4; TroVax?) has been tested in two open-label phase II studies in metastatic colorectal cancer patients alongside two chemotherapy regimens, 5-fluorouracil, folinic acid and irinotecan…
Zujian Cheng, Craig R. Lewis, Paul S. Thomas, Mark J. Raftery
The prognosis for patients with non-small cell lung cancer (NSCLC) remains poor in spite of better treatments. This relates mainly to the fact that the majority of patients present with advanced disease. There is a need to identify tools which can improve scr…
C. O. Da Fonseca, Raphael M. Teixeira, Ricardo Ramina, Giovana Kovaleski, Júlio Thome Silva, Janaína Nagel, Thereza Quirico-Santos
We report a case of recurrent glioblastoma (GBM) successfully treated with the Ras inhibitor monoterpene perillyl alcohol by intranasal administration. A 37-years-old white woman had been previously submitted to three neurosurgical procedures, in June 2000 fo…
Andreas Bannowsky, Hermann Ahlen, Klaus-Peter Jünemann
Moderate activity of systemic chemotherapy for advanced urothelial cancer has been reported for more than 30 years. Only with the advent of potent combination therapy clinically significant response rates as well as prolonged survival were documented. The the…
Anneli Nygaard, Karen-Lise Spindler, Christa Nyhus, Rikke Andersen, Anders Jakobsen
Lung cancer is one of the most common cancers in the western world, and closely related to smoking. The majority of the patients can not be offered treatment with curative intent. Palliative chemotherapy has limited effect but a considerable level of toxicity…
Gervain Mihály, Vörös Erika, Molnár Andor, Karcsú-Kis Gyöngyi, László Ferenc, László A. Ferenc
Twelve years following hemicolectomy for colon adenocarcinoma, a 75-year-old patient with prostate cancer was treated for 4 weeks with the antiandrogen nilutamide and then with the long-acting GnRH agonist buserelin. The serum testosterone and prostate-specif…
Brendon Coventry, Peter Hersey, Anne-Marie Halligan, Antonio Michele
Advanced Stage IV and IIIc melanoma has a dismal survival, with or without, standard chemotherapy. New therapies are required to improve survival and reduce morbidity. Repeated vaccine dosing does not appear to have been explored, so Vaccinia Melanoma Cell Ly…
Taiyab Aftab, Kuppa Srinivas Usha, Subbarao Sreedhar Amere
Pharmacological inhibition of Hsp90 has emerged as a novel anticancer treatment. In this study we have investigated the effect of Hsp90 inhibitor drug 17AAG combination with curcumin on human neuroblastoma cells. The 17AAG treatment of cells for 18 h induced…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).